Insulin Glargine: clinical trials recruiting now
3
Recruiting trials
9
Conditions studied
1
US states with sites
2
Countries
FDA drug label
- FDA-approved
- Yes. Insulin Glargine appears in the FDA drug-label database. Marketed as BASAGLAR KwikPen.
- Drug class
- Insulin Analog (FDA established pharmacologic class)
FDA-approved use
BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for treating diabetic ketoacidosis. ( 1 ) Limitations of Use BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.
Phase breakdown
Phase 3 1
Phase 4 2
Conditions being studied
Recruiting trials involving Insulin Glargine
- Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
- Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
- RCT Glargine vs NPH for Treatment of DM in Pregnancy
Common questions
Is Insulin Glargine FDA-approved?
Yes, marketed as BASAGLAR KwikPen.
How many recruiting trials involve Insulin Glargine?
3 recruiting trials across 9 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.